Economic Evaluation

• 6th Jan 2026

  Review of “Capturing the Impact of Constraints on the Cost-Effectiveness of Cell and Gene Therapies: A Systematic Review”

• 10th Nov 2025

  Preferences for advanced therapy medicinal products: understanding the published literature on the value of innovative health interventions

• 6th Oct 2025

  Ending the confusion: defining key terms in value assessment

• 15th Sep 2025

  Value attributes of advanced therapy medicinal products: a comprehensive literature review

• 23rd Jun 2025

  The value of hope – the case against inclusion in a value assessment framework for advanced therapies 

• 2nd Sep 2024

  A case study of the challenges of demonstrating cost-effectiveness in under-served patient populations: lecanemab for treating mild cognitive impairment or mild dementia caused by Alzheimer’s disease

• 19th Jun 2024

  Issues, Challenges and Opportunities for Economic Evaluations of Orphan Drugs in Rare Diseases: An Umbrella Review

• 6th Feb 2021

  How should value in healthcare be defined?

• 27th Dec 2020

  The need for pragmatic updates to the NICE methods

• 20th Jul 2020

  Should health interventions be assessed only for their cost-effectiveness?

• 3rd May 2020

  How should the most relevant and appropriate health outcomes for cost-effectiveness analysis be determined?

• 20th Apr 2020

  Thoughts on a universal health economic data source

• 20th Apr 2020

  Should clinical trials include economic endpoints?